Rush Immunotherapy Using IFN-Gamma for Aspirin in Acute Coronary Syndrome: Case Report

Abstract

Aspirin plays a key role in the secondary prevention of atherothrombotic events and thrombotic complications after stent implantation and aspirin sensitivity is a limitation for the implantation of bare-metal and drug-eluting coronary stents. Several desensitization protocols have been described. In this report, desensitization by introducing IFN-gamma as an immunomodulatory adjuvant was successful for the patients who required early invasive management and the prompt administration of aspirin but failed the classical desensitization by showing allergic symptoms and signs during desensitization.